The antagonist IL-4Rα mAb (dupilumab) approved for atopic dermatitis and asthma (Thibodeaux et al., 2019) primarily blocks the actions of IL-13 on epithelial cells, smooth muscle cells, and fibroblasts. This evidence concerns the gene IL4R and atopic eczema.